BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, Hober D, Dubuisson J, Rouillé Y, Séron K. (−)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 2012;55:720-9. [DOI: 10.1002/hep.24803] [Cited by in Crossref: 158] [Cited by in F6Publishing: 154] [Article Influence: 17.6] [Reference Citation Analysis]
Number Citing Articles
1 Galani BR, Sahuc ME, Njayou FN, Deloison G, Mkounga P, Feudjou WF, Brodin P, Rouillé Y, Nkengfack AE, Moundipa PF, Séron K. Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. Front Microbiol 2015;6:488. [PMID: 26029203 DOI: 10.3389/fmicb.2015.00488] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
2 Jakhmola S, Hazarika Z, Jha AN, Jha HC. In silico analysis of antiviral phytochemicals efficacy against Epstein-Barr virus glycoprotein H. J Biomol Struct Dyn 2021;:1-14. [PMID: 33438528 DOI: 10.1080/07391102.2020.1871074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kim M, Kim SY, Lee HW, Shin JS, Kim P, Jung YS, Jeong HS, Hyun JK, Lee CK. Inhibition of influenza virus internalization by (-)-epigallocatechin-3-gallate. Antiviral Res 2013;100:460-72. [PMID: 23954192 DOI: 10.1016/j.antiviral.2013.08.002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 8.9] [Reference Citation Analysis]
4 Carreño V. Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy. Aliment Pharmacol Ther 2014;39:148-62. [PMID: 24279580 DOI: 10.1111/apt.12562] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
5 Zeng YX, Wang S, Wei L, Cui YY, Chen YH. Proanthocyanidins: Components, Pharmacokinetics and Biomedical Properties. Am J Chin Med 2020;48:813-69. [PMID: 32536248 DOI: 10.1142/S0192415X2050041X] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
6 Chen C, Qiu H, Gong J, Liu Q, Xiao H, Chen X, Sun B, Yang R. (−)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. Arch Virol 2012;157:1301-12. [DOI: 10.1007/s00705-012-1304-0] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 6.4] [Reference Citation Analysis]
7 Mekky RY, El-Ekiaby N, El Sobky SA, Elemam NM, Youness RA, El-Sayed M, Hamza MT, Esmat G, Abdelaziz AI. Epigallocatechin gallate (EGCG) and miR-548m reduce HCV entry through repression of CD81 receptor in HCV cell models. Arch Virol 2019;164:1587-95. [PMID: 30949812 DOI: 10.1007/s00705-019-04232-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Elsebai MF, Koutsoudakis G, Saludes V, Pérez-Vilaró G, Turpeinen A, Mattila S, Pirttilä AM, Fontaine-Vive F, Mehiri M, Meyerhans A, Diez J. Pan-genotypic Hepatitis C Virus Inhibition by Natural Products Derived from the Wild Egyptian Artichoke. J Virol 2016;90:1918-30. [PMID: 26656684 DOI: 10.1128/JVI.02030-15] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
9 Gessner DK, Ringseis R, Eder K. Potential of plant polyphenols to combat oxidative stress and inflammatory processes in farm animals. J Anim Physiol Anim Nutr (Berl) 2017;101:605-28. [PMID: 27456323 DOI: 10.1111/jpn.12579] [Cited by in Crossref: 96] [Cited by in F6Publishing: 76] [Article Influence: 19.2] [Reference Citation Analysis]
10 Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study. J Biomol Struct Dyn 2021;39:4362-74. [PMID: 32568613 DOI: 10.1080/07391102.2020.1779818] [Cited by in Crossref: 34] [Cited by in F6Publishing: 44] [Article Influence: 34.0] [Reference Citation Analysis]
11 Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013;5:1292-1324. [PMID: 23698400 DOI: 10.3390/v5051292] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 11.6] [Reference Citation Analysis]
12 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Novel combined single dose anti-hepatitis C therapy: a pilot study. Sci Rep 2021;11:4623. [PMID: 33633233 DOI: 10.1038/s41598-021-84066-3] [Reference Citation Analysis]
13 Wang Z, Sun B, Zhu F. Epigallocatechin-3-gallate inhibit replication of white spot syndrome virus in Scylla paramamosain. Fish & Shellfish Immunology 2017;67:612-9. [DOI: 10.1016/j.fsi.2017.06.050] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
14 Fraga-Corral M, García-Oliveira P, Pereira AG, Lourenço-Lopes C, Jimenez-Lopez C, Prieto MA, Simal-Gandara J. Technological Application of Tannin-Based Extracts. Molecules 2020;25:E614. [PMID: 32019231 DOI: 10.3390/molecules25030614] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 38.0] [Reference Citation Analysis]
15 Liu CM, Chen CY, Lin YW. Estimation of tea catechin levels using micellar electrokinetic chromatography: a quantitative approach. Food Chem 2014;150:145-50. [PMID: 24360431 DOI: 10.1016/j.foodchem.2013.10.140] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Wang C, Hour M, Lai H, Chen C, Chang P, Huang S, Lin C. Epigallocatechin-3-gallate inhibits the early stages of Japanese encephalitis virus infection. Virus Research 2018;253:140-6. [DOI: 10.1016/j.virusres.2018.06.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
17 Lee M, Yang J, Jo E, Lee JY, Kim HY, Bartenschlager R, Shin EC, Bae YS, Windisch MP. A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner. Sci Rep 2017;7:44676. [PMID: 28333153 DOI: 10.1038/srep44676] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
18 Jain J, Kumari A, Somvanshi P, Grover A, Pai S, Sunil S. In silico analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus. F1000Res 2017;6:1601. [PMID: 29333236 DOI: 10.12688/f1000research.12301.2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Wang YZ, Li JL, Wang X, Zhang T, Ho WZ. (-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes. World J Gastroenterol 2017; 23(32): 5895-5903 [PMID: 28932081 DOI: 10.3748/wjg.v23.i32.5895] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
20 Halegoua-De Marzio D, Kraft WK, Daskalakis C, Ying X, Hawke RL, Navarro VJ. Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract. Clin Ther. 2012;34:2279-2285.e1. [PMID: 23153661 DOI: 10.1016/j.clinthera.2012.10.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
21 Bhat R, Adam AT, Lee JJ, Deloison G, Rouillé Y, Séron K, Rotella DP. Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors. Bioorg Med Chem Lett 2014;24:4162-5. [PMID: 25103601 DOI: 10.1016/j.bmcl.2014.07.051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
22 Domitrović R, Potočnjak I. A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives. Arch Toxicol 2016;90:39-79. [DOI: 10.1007/s00204-015-1580-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
23 Zhu J, Ou L, Zhou Y, Yang Z, Bie M. (-)-Epigallocatechin-3-gallate induces interferon-λ2 expression to anti-influenza A virus in human bronchial epithelial cells (BEAS-2B) through p38 MAPK signaling pathway. J Thorac Dis 2020;12:989-97. [PMID: 32274168 DOI: 10.21037/jtd.2020.03.20] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Galani BR, Sahuc ME, Sass G, Njayou FN, Loscher C, Mkounga P, Deloison G, Brodin P, Rouillé Y, Tiegs G, Séron K, Moundipa PF. Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. Arch Virol 2016;161:1169-81. [PMID: 26843184 DOI: 10.1007/s00705-016-2771-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
25 Bush CO, Pokrovskii MV, Saito R, Morganelli P, Canales E, Clarke MO, Lazerwith SE, Golde J, Reid BG, Babaoglu K. A small-molecule inhibitor of hepatitis C virus infectivity. Antimicrob Agents Chemother. 2014;58:386-396. [PMID: 24165192 DOI: 10.1128/aac.02083-13] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
26 Marzio DLHD, Fenkel JM. Complementary and alternative medications in hepatitis C infection. World J Hepatol 2014; 6(1): 9-16 [PMID: 24653790 DOI: 10.4254/wjh.v6.i1.9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Chung CY, Liu CH, Burnouf T, Wang GH, Chang SP, Jassey A, Tai CJ, Tai CJ, Huang CJ, Richardson CD, Yen MH, Lin CC, Lin LT. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry. Antiviral Res 2016;130:58-68. [PMID: 27012176 DOI: 10.1016/j.antiviral.2016.03.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
28 Hakobyan A, Arabyan E, Avetisyan A, Abroyan L, Hakobyan L, Zakaryan H. Apigenin inhibits African swine fever virus infection in vitro. Arch Virol 2016;161:3445-53. [PMID: 27638776 DOI: 10.1007/s00705-016-3061-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
29 Chowdhury P, Sahuc ME, Rouillé Y, Rivière C, Bonneau N, Vandeputte A, Brodin P, Goswami M, Bandyopadhyay T, Dubuisson J, Séron K. Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. PLoS One 2018;13:e0198226. [PMID: 30485282 DOI: 10.1371/journal.pone.0198226] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
30 Lai YH, Sun CP, Huang HC, Chen JC, Liu HK, Huang C. Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric mice. BMC Complement Altern Med 2018;18:248. [PMID: 30189898 DOI: 10.1186/s12906-018-2316-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
31 Lipson SM, Ozen FS, Louis S, Karthikeyan L. Comparison of α-glucosyl hesperidin of citrus fruits and epigallocatechin gallate of green tea on the Loss of Rotavirus Infectivity in Cell Culture. Front Microbiol 2015;6:359. [PMID: 25972850 DOI: 10.3389/fmicb.2015.00359] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
32 Mathew S, Fatima K, Fatmi MQ, Archunan G, Ilyas M, Begum N, Azhar E, Damanhouri G, Qadri I. Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds. PLoS One 2015;10:e0126510. [PMID: 26030803 DOI: 10.1371/journal.pone.0126510] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
33 Zhang L, Wu S, Wang D, Wan X, Zhang J. Epigallocatechin-3-gallate (EGCG) in or on Nanoparticles: Enhanced Stability and Bioavailability of EGCG Encapsulated in Nanoparticles or Targeted Delivery of Gold Nanoparticles Coated with EGCG. In: Sahu SC, Casciano DA, editors. Handbook of Nanotoxicology, Nanomedicine and Stem Cell Use in Toxicology. Chichester: John Wiley & Sons, Ltd; 2014. pp. 131-44. [DOI: 10.1002/9781118856017.ch8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
34 Lee M, Yang J, Park S, Jo E, Kim HY, Bae YS, Windisch MP. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner. Antiviral Res 2016;132:287-95. [PMID: 27387825 DOI: 10.1016/j.antiviral.2016.07.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
35 Ishida YI, Takeshita M, Kataoka H. Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism. World J Hepatol 2014; 6(12): 870-879 [PMID: 25544874 DOI: 10.4254/wjh.v6.i12.870] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
36 Xu J, Gu W, Li C, Li X, Xing G, Li Y, Song Y, Zheng W. Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha. J Nat Med 2016;70:584-91. [PMID: 26968537 DOI: 10.1007/s11418-016-0980-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
37 Tada R, Yamanaka D, Ogasawara M, Saito M, Ohno N, Kiyono H, Kunisawa J, Aramaki Y. Polymeric Caffeic Acid Is a Safer Mucosal Adjuvant That Augments Antigen-Specific Mucosal and Systemic Immune Responses in Mice. Mol Pharm 2018;15:4226-34. [PMID: 30107747 DOI: 10.1021/acs.molpharmaceut.8b00648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Bose M, Kamra M, Mullick R, Bhattacharya S, Das S, Karande AA. Identification of a flavonoid isolated from plum (Prunus domestica) as a potent inhibitor of Hepatitis C virus entry. Sci Rep 2017;7:3965. [PMID: 28638096 DOI: 10.1038/s41598-017-04358-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
39 Pacello F, D'Orazio M, Battistoni A. An ERp57-mediated disulphide exchange promotes the interaction between Burkholderia cenocepacia and epithelial respiratory cells. Sci Rep 2016;6:21140. [PMID: 26879174 DOI: 10.1038/srep21140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
40 Lee YH, Jang YH, Kim YS, Kim J, Seong BL. Evaluation of green tea extract as a safe personal hygiene against viral infections. J Biol Eng 2018;12:1. [PMID: 29339972 DOI: 10.1186/s13036-017-0092-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
41 Qian X, Xu C, Fang S, Zhao P, Wang Y, Liu H, Yuan W, Qi Z. Exosomal MicroRNAs Derived From Umbilical Mesenchymal Stem Cells Inhibit Hepatitis C Virus Infection. Stem Cells Transl Med 2016;5:1190-203. [PMID: 27496568 DOI: 10.5966/sctm.2015-0348] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 13.8] [Reference Citation Analysis]
42 Zhao C, Liu S, Li C, Yang L, Zu Y. In vitro evaluation of the antiviral activity of the synthetic epigallocatechin gallate analog-epigallocatechin gallate (EGCG) palmitate against porcine reproductive and respiratory syndrome virus. Viruses 2014;6:938-50. [PMID: 24566281 DOI: 10.3390/v6020938] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
43 Colpitts CC, Schang LM. A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans. J Virol 2014;88:7806-17. [PMID: 24789779 DOI: 10.1128/JVI.00896-14] [Cited by in Crossref: 77] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
44 Huan C, Xu W, Ni B, Guo T, Pan H, Jiang L, Li L, Yao J, Gao S. Epigallocatechin-3-Gallate, the Main Polyphenol in Green Tea, Inhibits Porcine Epidemic Diarrhea Virus In Vitro. Front Pharmacol 2021;12:628526. [PMID: 33692691 DOI: 10.3389/fphar.2021.628526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Rashed K, Sahuc M, Deloison G, Calland N, Brodin P, Rouillé Y, Séron K. Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro. Journal of Functional Foods 2014;11:185-91. [DOI: 10.1016/j.jff.2014.09.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
46 O'Shea D, Law J, Egli A, Douglas D, Lund G, Forester S, Lambert J, Law M, Burton DR, Tyrrell DL, Houghton M, Humar A, Kneteman N. Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. Liver Transpl 2016;22:324-32. [PMID: 26389583 DOI: 10.1002/lt.24344] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
47 Anggakusuma , Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, Brown RJ, Bankwitz D, Steinmann J. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut. 2014;63:1137-1149. [PMID: 23903236 DOI: 10.1136/gutjnl-2012-304299] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 13.0] [Reference Citation Analysis]
48 Henss L, Auste A, Schürmann C, Schmidt C, von Rhein C, Mühlebach MD, Schnierle BS. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection. J Gen Virol 2021;102. [PMID: 33830908 DOI: 10.1099/jgv.0.001574] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
49 Xu J, Xu Z, Zheng W. A Review of the Antiviral Role of Green Tea Catechins. Molecules. 2017;22:pii: E1337. [PMID: 28805687 DOI: 10.3390/molecules22081337] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 13.8] [Reference Citation Analysis]
50 Qian X, Jin Y, Chen H, Xu Q, Ren H, Zhu S, Tang H, Wang Y, Zhao P, Qi Z, Zhu Y. Trachelogenin, a novel inhibitor of hepatitis C virus entry through CD81. Journal of General Virology 2016;97:1134-44. [DOI: 10.1099/jgv.0.000432] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
51 Sahuc ME, Sahli R, Rivière C, Pène V, Lavie M, Vandeputte A, Brodin P, Rosenberg AR, Dubuisson J, Ksouri R, Rouillé Y, Sahpaz S, Séron K. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. J Virol 2019;93:e02009-18. [PMID: 30842319 DOI: 10.1128/JVI.02009-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
52 Ali SI, Sheikh WM, Rather MA, Venkatesalu V, Muzamil Bashir S, Nabi SU. Medicinal plants: Treasure for antiviral drug discovery. Phytother Res 2021;35:3447-83. [PMID: 33590931 DOI: 10.1002/ptr.7039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Vercauteren K, Leroux-roels G, Meuleman P. Blocking HCV entry as potential antiviral therapy. Future Virology 2012;7:547-61. [DOI: 10.2217/fvl.12.47] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
54 Reddy BU, Mullick R, Kumar A, Sudha G, Srinivasan N, Das S. Small molecule inhibitors of HCV replication from pomegranate. Sci Rep. 2014;4:5411. [PMID: 24958333 DOI: 10.1038/srep05411] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
55 Wang YQ, Li QS, Zheng XQ, Lu JL, Liang YR. Antiviral Effects of Green Tea EGCG and Its Potential Application against COVID-19. Molecules 2021;26:3962. [PMID: 34209485 DOI: 10.3390/molecules26133962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Shimizu JF, Pereira CM, Bittar C, Batista MN, Campos GRF, da Silva S, Cintra ACO, Zothner C, Harris M, Sampaio SV, Aquino VH, Rahal P, Jardim ACG. Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle. PLoS One 2017;12:e0187857. [PMID: 29141010 DOI: 10.1371/journal.pone.0187857] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
57 Goh VSL, Mok CK, Chu JJH. Antiviral Natural Products for Arbovirus Infections. Molecules 2020;25:E2796. [PMID: 32560438 DOI: 10.3390/molecules25122796] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
58 Imran M, Manzoor S, Khattak NM, Khalid M, Ahmed QL, Parvaiz F, Tariq M, Ashraf J, Ashraf W, Azam S, Ashraf M. Current and future therapies for hepatitis C virus infection: from viral proteins to host targets. Arch Virol 2014;159:831-46. [DOI: 10.1007/s00705-013-1803-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
59 Yu X, Sainz B Jr, Petukhov PA, Uprichard SL. Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrob Agents Chemother 2012;56:6109-20. [PMID: 22948883 DOI: 10.1128/AAC.01413-12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
60 Roumy V, Ruiz L, Ruiz Macedo JC, Gutierrez-Choquevilca AL, Samaillie J, Encinas LA, Mesia WR, Ricopa Cotrina HE, Rivière C, Sahpaz S, Bordage S, Garçon G, Dubuisson J, Anthérieu S, Seron K, Hennebelle T. Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource. J Ethnopharmacol 2020;255:112735. [PMID: 32147478 DOI: 10.1016/j.jep.2020.112735] [Reference Citation Analysis]
61 Shahid F, Noreen, Ali R, Badshah SL, Jamal SB, Ullah R, Bari A, Majid Mahmood H, Sohaib M, Akber Ansari S. Identification of Potential HCV Inhibitors Based on the Interaction of Epigallocatechin-3-Gallate with Viral Envelope Proteins. Molecules 2021;26:1257. [PMID: 33652639 DOI: 10.3390/molecules26051257] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Hao S, Yang D, Zhao L, Shi F, Ye G, Fu H, Lin J, Guo H, He R, Li J, Chen H, Khan MF, Li Y, Tang H. EGCG-Mediated Potential Inhibition of Biofilm Development and Quorum Sensing in Pseudomonas aeruginosa. Int J Mol Sci 2021;22:4946. [PMID: 34066609 DOI: 10.3390/ijms22094946] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Colpitts CC, Baumert TF. Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals. Hepatol Int 2016;10:741-8. [DOI: 10.1007/s12072-016-9724-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
64 Lv XQ, Zou LL, Tan JL, Li H, Li JR, Liu NN, Dong B, Song DQ, Peng ZG. Aloperine inhibits hepatitis C virus entry into cells by disturbing internalisation from endocytosis to the membrane fusion process. Eur J Pharmacol 2020;883:173323. [PMID: 32622669 DOI: 10.1016/j.ejphar.2020.173323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Zakaryan H, Arabyan E, Oo A, Zandi K. Flavonoids: promising natural compounds against viral infections. Arch Virol 2017;162:2539-51. [PMID: 28547385 DOI: 10.1007/s00705-017-3417-y] [Cited by in Crossref: 126] [Cited by in F6Publishing: 98] [Article Influence: 31.5] [Reference Citation Analysis]
66 Kumar D, Sharma N, Aarthy M, Singh SK, Giri R. Mechanistic Insights into Zika Virus NS3 Helicase Inhibition by Epigallocatechin-3-Gallate. ACS Omega 2020;5:11217-26. [PMID: 32455246 DOI: 10.1021/acsomega.0c01353] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
67 Lin LT, Hsu WC, Lin CC. Antiviral natural products and herbal medicines. J Tradit Complement Med 2014;4:24-35. [PMID: 24872930 DOI: 10.4103/2225-4110.124335] [Cited by in Crossref: 176] [Cited by in F6Publishing: 143] [Article Influence: 25.1] [Reference Citation Analysis]
68 Shimizu JF, Lima CS, Pereira CM, Bittar C, Batista MN, Nazaré AC, Polaquini CR, Zothner C, Harris M, Rahal P, Regasini LO, Jardim ACG. Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry. Sci Rep 2017;7:16127. [PMID: 29170411 DOI: 10.1038/s41598-017-16336-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
69 Lassmann B, Arumugaswami V, Chew KW, Lewis MJ. A new system to measure and compare hepatitis C virus replication capacity using full-length, replication competent viruses. J Virol Methods 2013;194:82-8. [PMID: 23973740 DOI: 10.1016/j.jviromet.2013.08.009] [Reference Citation Analysis]
70 [DOI: 10.1101/530600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, McKeating JA, Leroux-Roels G, Baumert TF, Patel AH, Meuleman P. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. Hepatology 2016;63:1120-34. [PMID: 26710081 DOI: 10.1002/hep.28428] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
72 Moreno FS, Heidor R, Pogribny IP. Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents. Nutrition and Cancer 2016;68:719-33. [DOI: 10.1080/01635581.2016.1180410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
73 Lin YT, Wu YH, Tseng CK, Lin CK, Chen WC, Hsu YC, Lee JC. Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 and attenuate virus-induced inflammation. PLoS One. 2013;8:e54466. [PMID: 23365670 DOI: 10.1371/journal.pone.0054466] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
74 Lee HS, Jun JH, Jung EH, Koo BA, Kim YS. Epigalloccatechin-3-gallate inhibits ocular neovascularization and vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation. Molecules 2014;19:12150-72. [PMID: 25123184 DOI: 10.3390/molecules190812150] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
75 Nguyen LP, Park C, Luong TTD, Park EM, Choi DH, Han KM, Mai HN, Nguyen HC, Lim YS, Hwang SB. 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry. Sci Rep 2019;9:7288. [PMID: 31086268 DOI: 10.1038/s41598-019-43783-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Song JM. Anti-infective potential of catechins and their derivatives against viral hepatitis. Clin Exp Vaccine Res 2018;7:37-42. [PMID: 29399578 DOI: 10.7774/cevr.2018.7.1.37] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
77 Liu S, Chen R, Hagedorn CH. Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells. PLoS One 2015;10:e0131358. [PMID: 26186636 DOI: 10.1371/journal.pone.0131358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
78 Pollicino T, Musolino C, Irrera N, Bitto A, Lombardo D, Timmoneri M, Minutoli L, Raimondo G, Squadrito G, Squadrito F, Altavilla D. Flavocoxid exerts a potent antiviral effect against hepatitis B virus. Inflamm Res 2018;67:89-103. [DOI: 10.1007/s00011-017-1099-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
79 Villalaín J. Epigallocatechin-3-gallate location and interaction with late endosomal and plasma membrane model membranes by molecular dynamics. J Biomol Struct Dyn 2019;37:3122-34. [PMID: 30081748 DOI: 10.1080/07391102.2018.1508372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
80 Wahyuni TS, Tumewu L, Permanasari AA, Apriani E, Adianti M, Rahman A, Widyawaruyanti A, Lusida MI, Fuad A, Soetjipto, Nasronudin, Fuchino H, Kawahara N, Shoji I, Deng L, Aoki C, Hotta H. Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus. Virol J 2013;10:259. [PMID: 24089993 DOI: 10.1186/1743-422X-10-259] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
81 Blaising J, Pécheur EI. Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies. Biochimie. 2013;95:96-102. [PMID: 22884392 DOI: 10.1016/j.biochi.2012.07.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
82 Zhu Y, Gu X, Zhang M, Lv X, Zhang C, Li J, Hu Z, Wu Q, Zhang R, Wei J, Huang R, Wang B, Wang Q, Wang G. Epigallocatechin-3-gallate exhibits antiviral effects against the duck Tembusu virus via blocking virus entry and upregulating type I interferons. Poult Sci 2021;100:100989. [PMID: 33647721 DOI: 10.1016/j.psj.2021.01.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
83 LeBlanc EV, Kim Y, Capicciotti CJ, Colpitts CC. Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies. Pathogens 2021;10:685. [PMID: 34205894 DOI: 10.3390/pathogens10060685] [Reference Citation Analysis]
84 Liu J, Bodnar BH, Meng F, Khan AI, Wang X, Saribas S, Wang T, Lohani SC, Wang P, Wei Z, Luo J, Zhou L, Wu J, Luo G, Li Q, Hu W, Ho W. Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. Cell Biosci 2021;11:168. [PMID: 34461999 DOI: 10.1186/s13578-021-00680-8] [Reference Citation Analysis]
85 Saha S, Nandi R, Vishwakarma P, Prakash A, Kumar D. Discovering Potential RNA Dependent RNA Polymerase Inhibitors as Prospective Drugs Against COVID-19: An in silico Approach. Front Pharmacol 2021;12:634047. [PMID: 33716752 DOI: 10.3389/fphar.2021.634047] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Wang L, Liang R, Gao Y, Li Y, Deng X, Xiang R, Zhang Y, Ying T, Jiang S, Yu F. Development of Small-Molecule Inhibitors Against Zika Virus Infection. Front Microbiol 2019;10:2725. [PMID: 31866959 DOI: 10.3389/fmicb.2019.02725] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
87 He X, Gao B, Zhou L, Xiong S. Green Tea Polyphenol Epigallocatechin-3-gallate-Alleviated Coxsackievirus B3-induced Myocarditis Through Inhibiting Viral Replication but Not Through Inhibiting Inflammatory Responses. J Cardiovasc Pharmacol 2017;69:41-7. [PMID: 27753702 DOI: 10.1097/FJC.0000000000000439] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Mesalam AA, Vercauteren K, Meuleman P. Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses 2016;8:E176. [PMID: 27338446 DOI: 10.3390/v8060176] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
89 Anwar MF, Khalid R, Hasanain A, Naeem S, Zarina S, Abidi SH, Ali S. Application of an integrated cheminformatics-molecular docking approach for discovery for physicochemically similar analogs of fluoroquinolones as putative HCV inhibitors. Comput Biol Chem 2020;84:107167. [PMID: 31855781 DOI: 10.1016/j.compbiolchem.2019.107167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
90 Vázquez-Calvo Á, Jiménez de Oya N, Martín-Acebes MA, Garcia-Moruno E, Saiz JC. Antiviral Properties of the Natural Polyphenols Delphinidin and Epigallocatechin Gallate against the Flaviviruses West Nile Virus, Zika Virus, and Dengue Virus. Front Microbiol 2017;8:1314. [PMID: 28744282 DOI: 10.3389/fmicb.2017.01314] [Cited by in Crossref: 84] [Cited by in F6Publishing: 71] [Article Influence: 21.0] [Reference Citation Analysis]
91 Mekky RY, El-Ekiaby NM, Hamza MT, Elemam NM, El-Sayed M, Esmat G, Abdelaziz AI. Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor. J Infect 2015;70:78-87. [PMID: 25218426 DOI: 10.1016/j.jinf.2014.08.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
92 Li S, Tan HY, Wang N, Cheung F, Hong M, Feng Y. The Potential and Action Mechanism of Polyphenols in the Treatment of Liver Diseases. Oxid Med Cell Longev 2018;2018:8394818. [PMID: 29507653 DOI: 10.1155/2018/8394818] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 10.3] [Reference Citation Analysis]
93 Ferreira PG, Ferraz AC, Figueiredo JE, Lima CF, Rodrigues VG, Taranto AG, Ferreira JMS, Brandão GC, Vieira-filho SA, Duarte LP, de Brito Magalhães CL, de Magalhães JC. Detection of the antiviral activity of epicatechin isolated from Salacia crassifolia (Celastraceae) against Mayaro virus based on protein C homology modelling and virtual screening. Arch Virol 2018;163:1567-76. [DOI: 10.1007/s00705-018-3774-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
94 Zou M, Liu H, Li J, Yao X, Chen Y, Ke C, Liu S. Structure-activity relationship of flavonoid bifunctional inhibitors against Zika virus infection. Biochem Pharmacol 2020;177:113962. [PMID: 32272109 DOI: 10.1016/j.bcp.2020.113962] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
95 Qian XJ, Zhang XL, Zhao P, Jin YS, Chen HS, Xu QQ, Ren H, Zhu SY, Tang HL, Zhu YZ. A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes. Sci Rep. 2016;6:27268. [PMID: 27252043 DOI: 10.1038/srep27268] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
96 Kaihatsu K, Yamabe M, Ebara Y. Antiviral Mechanism of Action of Epigallocatechin-3-O-gallate and Its Fatty Acid Esters. Molecules 2018;23:E2475. [PMID: 30262731 DOI: 10.3390/molecules23102475] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 12.7] [Reference Citation Analysis]
97 Millet JK, Tang T, Nathan L, Jaimes JA, Hsu HL, Daniel S, Whittaker GR. Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting. J Vis Exp 2019. [PMID: 30882796 DOI: 10.3791/59010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 15.0] [Reference Citation Analysis]
98 Dhiman RK. The Green Tea Polyphenol, Epigallocatechin-3-Gallate (EGCG)-One Step Forward in Antiviral Therapy Against Hepatitis C Virus. J Clin Exp Hepatol 2011;1:159-60. [PMID: 25755380 DOI: 10.1016/S0973-6883(11)60232-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
99 Isaacs CE, Xu W. Theaflavin-3,3'-digallate and lactic acid combinations reduce herpes simplex virus infectivity. Antimicrob Agents Chemother 2013;57:3806-14. [PMID: 23716050 DOI: 10.1128/AAC.00659-13] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
100 Maiti S, Banerjee A. Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study. Drug Dev Res 2021;82:86-96. [PMID: 32770567 DOI: 10.1002/ddr.21730] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
101 Meng XH, Li N, Zhu HT, Wang D, Yang CR, Zhang YJ. Plant Resources, Chemical Constituents, and Bioactivities of Tea Plants from the Genus Camellia Section Thea. J Agric Food Chem 2019;67:5318-49. [PMID: 30449099 DOI: 10.1021/acs.jafc.8b05037] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
102 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study. Sci Rep 2019;9:13593. [PMID: 31537880 DOI: 10.1038/s41598-019-49973-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
103 Qi Y, Xiang Y, Wang J, Qi Y, Li J, Niu J, Zhong J. Inhibition of hepatitis C virus infection by polyoxometalates. Antiviral Res 2013;100:392-8. [PMID: 24025401 DOI: 10.1016/j.antiviral.2013.08.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
104 Ismail NA, Jusoh SA. Molecular Docking and Molecular Dynamics Simulation Studies to Predict Flavonoid Binding on the Surface of DENV2 E Protein. Interdiscip Sci 2017;9:499-511. [PMID: 26969331 DOI: 10.1007/s12539-016-0157-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
105 Jiang X, Tan J, Wang Y, Chen J, Li J, Jiang Z, Quan Y, Jin J, Li Y, Cen S, Li Y, Peng Z, Li Z. 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. J Med Chem 2020;63:5972-89. [PMID: 32378892 DOI: 10.1021/acs.jmedchem.0c00232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
106 Marín L, Miguélez EM, Villar CJ, Lombó F. Bioavailability of dietary polyphenols and gut microbiota metabolism: antimicrobial properties. Biomed Res Int 2015;2015:905215. [PMID: 25802870 DOI: 10.1155/2015/905215] [Cited by in Crossref: 355] [Cited by in F6Publishing: 296] [Article Influence: 59.2] [Reference Citation Analysis]
107 Lu JW, Hsieh PS, Lin CC, Hu MK, Huang SM, Wang YM, Liang CY, Gong Z, Ho YJ. Synergistic effects of combination treatment using EGCG and suramin against the chikungunya virus. Biochem Biophys Res Commun 2017;491:595-602. [PMID: 28760340 DOI: 10.1016/j.bbrc.2017.07.157] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
108 [DOI: 10.1101/325126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Calland N, Dubuisson J, Rouillé Y, Séron K. Hepatitis C virus and natural compounds: a new antiviral approach? Viruses 2012;4:2197-217. [PMID: 23202460 DOI: 10.3390/v4102197] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
110 Clain E, Haddad JG, Koishi AC, Sinigaglia L, Rachidi W, Desprès P, Duarte Dos Santos CN, Guiraud P, Jouvenet N, El Kalamouni C. The Polyphenol-Rich Extract from Psiloxylon mauritianum, an Endemic Medicinal Plant from Reunion Island, Inhibits the Early Stages of Dengue and Zika Virus Infection. Int J Mol Sci 2019;20:E1860. [PMID: 30991717 DOI: 10.3390/ijms20081860] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
111 Fofana I, Jilg N, Chung RT, Baumert TF. Entry inhibitors and future treatment of hepatitis C. Antiviral Res 2014;104:136-42. [PMID: 24525381 DOI: 10.1016/j.antiviral.2014.02.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
112 Chamoun-Emanuelli AM, Pecheur EI, Simeon RL, Huang D, Cremer PS, Chen Z. Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother. 2013;57:2571-2581. [PMID: 23529728 DOI: 10.1128/aac.02593-12] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
113 Ge M, Xiao Y, Chen H, Luo F, Du G, Zeng F. Multiple antiviral approaches of (-)-epigallocatechin-3-gallate (EGCG) against porcine reproductive and respiratory syndrome virus infection in vitro. Antiviral Res 2018;158:52-62. [PMID: 30048655 DOI: 10.1016/j.antiviral.2018.07.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
114 Pillukat MH, Bester C, Hensel A, Lechtenberg M, Petereit F, Beckebaum S, Müller KM, Schmidt HH. Concentrated green tea extract induces severe acute hepatitis in a 63-year-old woman--a case report with pharmaceutical analysis. J Ethnopharmacol 2014;155:165-70. [PMID: 24862489 DOI: 10.1016/j.jep.2014.05.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
115 Qian XJ, Zhu YZ, Zhao P, Qi ZT. Entry inhibitors: New advances in HCV treatment. Emerg Microbes Infect 2016;5:e3. [PMID: 26733381 DOI: 10.1038/emi.2016.3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
116 Jain J, Kumari A, Somvanshi P, Grover A, Pai S, Sunil S. In silico analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus. F1000Res 2017;6:1601. [PMID: 29333236 DOI: 10.12688/f1000research.12301.2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
117 Weber C, Sliva K, von Rhein C, Kümmerer BM, Schnierle BS. The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Antiviral Res 2015;113:1-3. [PMID: 25446334 DOI: 10.1016/j.antiviral.2014.11.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 8.1] [Reference Citation Analysis]
118 Calland N, Sahuc ME, Belouzard S, Pène V, Bonnafous P, Mesalam AA, Deloison G, Descamps V, Sahpaz S, Wychowski C, Lambert O, Brodin P, Duverlie G, Meuleman P, Rosenberg AR, Dubuisson J, Rouillé Y, Séron K. Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. J Virol 2015;89:10053-63. [PMID: 26202241 DOI: 10.1128/JVI.01473-15] [Cited by in Crossref: 68] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
119 Ahmed M, Henson DA, Sanderson MC, Nieman DC, Gillitt ND, Lila MA. The protective effects of a polyphenol-enriched protein powder on exercise-induced susceptibility to virus infection. Phytother Res 2014;28:1829-36. [PMID: 25088029 DOI: 10.1002/ptr.5208] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
120 Menegazzi M, Campagnari R, Bertoldi M, Crupi R, Di Paola R, Cuzzocrea S. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19? Int J Mol Sci 2020;21:E5171. [PMID: 32708322 DOI: 10.3390/ijms21145171] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
121 Mhatre S, Srivastava T, Naik S, Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review. Phytomedicine 2021;85:153286. [PMID: 32741697 DOI: 10.1016/j.phymed.2020.153286] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 27.0] [Reference Citation Analysis]
122 Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoël M, Leyssen P, Neyts J, Zeisel MB, Baumert TF. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 2015;64:483-94. [PMID: 24848265 DOI: 10.1136/gutjnl-2013-306155] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 9.6] [Reference Citation Analysis]
123 Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol 2013;168:1059-73. [PMID: 23072320 DOI: 10.1111/bph.12009] [Cited by in Crossref: 232] [Cited by in F6Publishing: 214] [Article Influence: 29.0] [Reference Citation Analysis]
124 Vu TH, Le Lamer AC, Lalli C, Boustie J, Samson M, Lohézic-Le Dévéhat F, Le Seyec J. Depsides: lichen metabolites active against hepatitis C virus. PLoS One 2015;10:e0120405. [PMID: 25793970 DOI: 10.1371/journal.pone.0120405] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
125 Granja A, Pinheiro M, Reis S. Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy. Nutrients 2016;8:E307. [PMID: 27213442 DOI: 10.3390/nu8050307] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 11.2] [Reference Citation Analysis]
126 Wang ZY, Li YQ, Guo ZW, Zhou XH, Lu MD, Xue TC, Gao B. ERK1/2-HNF4α axis is involved in epigallocatechin-3-gallate inhibition of HBV replication. Acta Pharmacol Sin 2020;41:278-85. [PMID: 31554961 DOI: 10.1038/s41401-019-0302-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
127 Yu JS, Chen WC, Tseng CK, Lin CK, Hsu YC, Chen YH, Lee JC. Sulforaphane Suppresses Hepatitis C Virus Replication by Up-Regulating Heme Oxygenase-1 Expression through PI3K/Nrf2 Pathway. PLoS One 2016;11:e0152236. [PMID: 27023634 DOI: 10.1371/journal.pone.0152236] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
128 Bose M, Kamra M, Mullick R, Bhattacharya S, Das S, Karande AA. A plant-derived dehydrorotenoid: a new inhibitor of hepatitis C virus entry. FEBS Lett 2017;591:1305-17. [DOI: 10.1002/1873-3468.12629] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
129 Séron K, Sahuc M, Rouillé Y. Natural Products and Hepatitis C Virus. In: Mérillon J, Riviere C, editors. Natural Antimicrobial Agents. Cham: Springer International Publishing; 2018. pp. 289-327. [DOI: 10.1007/978-3-319-67045-4_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
130 Tsou LK, Yount JS, Hang HC. Epigallocatechin-3-gallate inhibits bacterial virulence and invasion of host cells. Bioorg Med Chem 2017;25:2883-7. [PMID: 28325635 DOI: 10.1016/j.bmc.2017.03.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
131 Kumar N, Sharma S, Kumar R, Tripathi BN, Barua S, Ly H, Rouse BT. Host-Directed Antiviral Therapy. Clin Microbiol Rev 2020;33:e00168-19. [PMID: 32404434 DOI: 10.1128/CMR.00168-19] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
132 Eyre NS, Helbig KJ, Beard MR. Current and future targets of antiviral therapy in the hepatitis C virus life cycle. Future Virology 2014;9:947-65. [DOI: 10.2217/fvl.14.83] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
133 Fénéant L, Potel J, François C, Sané F, Douam F, Belouzard S, Calland N, Vausselin T, Rouillé Y, Descamps V, Baumert TF, Duverlie G, Lavillette D, Hober D, Dubuisson J, Wychowski C, Cocquerel L. New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. J Virol 2015;89:8346-64. [PMID: 26041282 DOI: 10.1128/JVI.00192-15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
134 Carneiro BM, Batista MN, Braga ACS, Nogueira ML, Rahal P. The green tea molecule EGCG inhibits Zika virus entry. Virology 2016;496:215-8. [DOI: 10.1016/j.virol.2016.06.012] [Cited by in Crossref: 111] [Cited by in F6Publishing: 92] [Article Influence: 22.2] [Reference Citation Analysis]
135 Zhou X, Sun P, Lucendo-Villarin B, Angus AG, Szkolnicka D, Cameron K, Farnworth SL, Patel AH, Hay DC. Modulating innate immunity improves hepatitis C virus infection and replication in stem cell-derived hepatocytes. Stem Cell Reports. 2014;3:204-214. [PMID: 25068132 DOI: 10.1016/j.stemcr.2014.04.018] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
136 Azocar J, Diaz A. Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection. World J Gastroenterol 2013; 19(7): 1085-1090 [PMID: 23467073 DOI: 10.3748/wjg.v19.i7.1085] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
137 Jardim ACG, Shimizu JF, Rahal P, Harris M. Plant-derived antivirals against hepatitis c virus infection. Virol J 2018;15:34. [PMID: 29439720 DOI: 10.1186/s12985-018-0945-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
138 Steinmann E, Pietschmann T. Cell culture systems for hepatitis C virus. Curr Top Microbiol Immunol. 2013;369:17-48. [PMID: 23463196 DOI: 10.1007/978-3-642-27340-7_2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
139 Al Olaby RR, Cocquerel L, Zemla A, Saas L, Dubuisson J, Vielmetter J, Marcotrigiano J, Khan AG, Vences Catalan F, Perryman AL, Freundlich JS, Forli S, Levy S, Balhorn R, Azzazy HM. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein. PLoS One 2014;9:e111333. [PMID: 25357246 DOI: 10.1371/journal.pone.0111333] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
140 Khan M, Rauf W, Habib F, Rahman M, Iqbal M. Screening and identification of bioactive compounds from citrus against non-structural protein 3 protease of hepatitis C virus genotype 3a by fluorescence resonance energy transfer assay and mass spectrometry. World J Hepatol 2020; 12(11): 976-992 [PMID: 33312423 DOI: 10.4254/wjh.v12.i11.976] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Moustafa RI, Haddad JG, Linna L, Hanoulle X, Descamps V, Mesalam AA, Baumert TF, Duverlie G, Meuleman P, Dubuisson J, Lavie M. Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain. J Virol 2018;92:e00939-18. [PMID: 30068644 DOI: 10.1128/JVI.00939-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
142 El-Tantawy WH, Temraz A. Natural products for the management of the hepatitis C virus: a biochemical review. Arch Physiol Biochem 2020;126:116-28. [PMID: 30269604 DOI: 10.1080/13813455.2018.1498902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Lin LT, Chung CY, Hsu WC, Chang SP, Hung TC, Shields J, Russell RS, Lin CC, Li CF, Yen MH, Tyrrell DL, Lin CC, Richardson CD. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. J Hepatol 2015;62:541-8. [PMID: 25450204 DOI: 10.1016/j.jhep.2014.10.040] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
144 Zhu YZ, Qian XJ, Zhao P, Qi ZT. How hepatitis C virus invades hepatocytes: The mystery of viral entry. World J Gastroenterol 2014; 20(13): 3457-3467 [PMID: 24707128 DOI: 10.3748/wjg.v20.i13.3457] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
145 Huan C, Xu W, Guo T, Pan H, Zou H, Jiang L, Li C, Gao S. (-)-Epigallocatechin-3-Gallate Inhibits the Life Cycle of Pseudorabies Virus In Vitro and Protects Mice Against Fatal Infection. Front Cell Infect Microbiol 2020;10:616895. [PMID: 33520741 DOI: 10.3389/fcimb.2020.616895] [Reference Citation Analysis]
146 Huang Q, Liu X, Zhao G, Hu T, Wang Y. Potential and challenges of tannins as an alternative to in-feed antibiotics for farm animal production. Anim Nutr 2018;4:137-50. [PMID: 30140753 DOI: 10.1016/j.aninu.2017.09.004] [Cited by in Crossref: 114] [Cited by in F6Publishing: 75] [Article Influence: 28.5] [Reference Citation Analysis]
147 Wu D, Liu Z, Wang Y, Zhang Q, Li J, Zhong P, Xie Z, Ji A, Li Y. Epigallocatechin-3-Gallate Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via Inhibition of Apoptosis and Promotion of Autophagy through the ROS/MAPK Signaling Pathway. Oxid Med Cell Longev 2021;2021:5599997. [PMID: 33953830 DOI: 10.1155/2021/5599997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
148 Shen H, Yamashita A, Nakakoshi M, Yokoe H, Sudo M, Kasai H, Tanaka T, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Shindo H, Maekawa S, Enomoto N, Tsubuki M, Moriishi K. Inhibitory effects of caffeic acid phenethyl ester derivatives on replication of hepatitis C virus. PLoS One 2013;8:e82299. [PMID: 24358168 DOI: 10.1371/journal.pone.0082299] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
149 Zhao Z, Feng M, Wan J, Zheng X, Teng C, Xie X, Pan W, Hu B, Huang J, Liu Z, Wu J, Cai S. Research progress of epigallocatechin-3-gallate (EGCG) on anti-pathogenic microbes and immune regulation activities. Food Funct 2021;12:9607-19. [PMID: 34549212 DOI: 10.1039/d1fo01352a] [Reference Citation Analysis]
150 Wang Y, Li J, Wang X, Peña JC, Li K, Zhang T, Ho W. (-)-Epigallocatechin-3-Gallate Enhances Hepatitis C Virus Double-Stranded RNA Intermediates-Triggered Innate Immune Responses in Hepatocytes. Sci Rep 2016;6:21595. [PMID: 26879672 DOI: 10.1038/srep21595] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
151 Huang HC, Tao MH, Hung TM, Chen JC, Lin ZJ, Huang C. (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res. 2014;111:100-111. [PMID: 25260897 DOI: 10.1016/j.antiviral.2014.09.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 10.1] [Reference Citation Analysis]
152 Haddad JG, Rouillé Y, Hanoulle X, Descamps V, Hamze M, Dabboussi F, Baumert TF, Duverlie G, Lavie M, Dubuisson J. Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. J Virol 2017;91:e00048-17. [PMID: 28179528 DOI: 10.1128/JVI.00048-17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
153 Mathew S, Faheem M, Archunan G, Ilyas M, Begum N, Jahangir S, Qadri I, Qahtani MA, Mathew S. In silico studies of medicinal compounds against hepatitis C capsid protein from north India. Bioinform Biol Insights. 2014;8:159-168. [PMID: 25002815 DOI: 10.4137/bbi.s15211] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
154 Zhong L, Hu J, Shu W, Gao B, Xiong S. Epigallocatechin-3-gallate opposes HBV-induced incomplete autophagy by enhancing lysosomal acidification, which is unfavorable for HBV replication. Cell Death Dis 2015;6:e1770. [PMID: 25996297 DOI: 10.1038/cddis.2015.136] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]